

Dr. Thomas M. Stackhouse

Dr. Stackhouse is the Associate Director for the Technology Transfer Center (TTC) at the National Cancer Institute, NIH. In this position, he oversees the patent portfolio and marketing activities for the National Cancer Institute (NCI). Dr. Stackhouse also oversees the technology transfer and partnering agreements and activities for the staff on the NCI-Frederick campus, which includes NCI intramural laboratories and the laboratories of its Federally Funded Research and Development Center (FFRDC).

In addition, Dr. Stackhouse leads the TTC staff coordinating intellectual property parameters and guidelines for several key NCI initiatives including: the Full-Length cDNA Initiative, the Institute of Chemical Genomics, NCI Proteomics Program, NCI's Alliance for Nanotechnology in Cancer, caHUB, and the NCI Chemical Biology Consortium. Dr. Stackhouse works closely with state and local economic development groups to foster new partnerships which facilitate the use of NCI technologies and expertise to advance the public health and stimulate the nation's economies. He is also a member of the Executive Board for the Federal Laboratory Consortium.

Prior to joining the NCI-Technology Transfer staff in 1996, Dr. Stackhouse received his Ph.D. in Biochemistry from the University of California, Davis. He spent several years as a Developmental Scientist for a major pharmaceutical company and later was part of the research team that discovered the VHL tumor suppressor gene. Dr. Stackhouse received the National Institutes of Health Award of Merit for his outstanding management of the NCI-Frederick Technology Transfer Office.